Remember to get your questions to me for David today. They are very near to starting their study.
Entest BioMedical Projecting Near Term Start Up of Study on Stem Cell and Laser Treatment for COPD at Bio-Matrix Scientific Group's Stem Cell Research
Entest Acquires First of Several Photoceutical Devices for Use in Developing Proprietary Laser Device, ENT-576, Which Will Be Coupled With Stem Cell Therapy in COPD Treatment
January 22, 2010:
Entest BioMedical Inc. (OTCBB: ENTB) announced that it has acquired the first of several photoceutical devices it will be using in the development of its proprietary laser device, ENT-576. This laser device will be used in conjunction with stem cell therapy to enhance efficacy in the regenerative treatment of Chronic Obstructive Pulmonary Disease (COPD).
The Company's Chairman & CEO David Koos stated, "We are excited with this first step in moving towards a specialized laser device that will augment stem cell therapy for treating COPD. We believe the ENT-576 can be utilized to 'paint' damaged lung tissue with laser irradiation allowing stem cells therapeutic treatment to 'spot focus' on the damaged tissue resulting in not only a reduction of progression but also an actual reversal of the effects of COPD."
A spokesperson for Bio-Matrix Scientific Group Inc. (OTCBB: BMSN) noted that it is anticipated this research will start up shortly at its 15,000 sq. ft. stem cell research facility. The projected outcomes of this study will be the development of ENT-576, a specialized laser device, as well as an effective stem cell therapy for treating COPD.
COPD is the 4th leading cause of death in the United States and there is currently no known cure.
About Entest BioMedical Inc.:
Entest BioMedical Inc. (OTCBB: ENTB) is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), immuno-cancer therapies, testing procedures for diabetes, stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation). ENT-576 is a proprietary laser device currently under development by Entest. The Company has filed 3 patent applications relating to the treatment of COPD.
About Bio-Matrix Scientific Group:
Bio-Matrix Scientific Group Inc. (OTCBB: BMSN) is the majority owner of Entest BioMedical Inc. BMSN is a biotechnology company headquartered in San Diego, Ca. with a 15,000 sq. ft. facility that houses two secure cryogenic stem cell banks, three research laboratories, aseptic cellular/tissue class 10,000/100 processing lab, hematology, microbiology and flow cytometry laboratories. David Koos serves as Chairman & CEO concurrently for BMSN and ENTB.
Forward-looking statements:
This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Entest BioMedical Projecting Near Term Start Up of Study on Stem Cell and Laser Treatment for COPD at Bio-Matrix Scientific Group's Stem Cell Research
Entest Acquires First of Several Photoceutical Devices for Use in Developing Proprietary Laser Device, ENT-576, Which Will Be Coupled With Stem Cell Therapy in COPD Treatment
January 22, 2010:
Entest BioMedical Inc. (OTCBB: ENTB) announced that it has acquired the first of several photoceutical devices it will be using in the development of its proprietary laser device, ENT-576. This laser device will be used in conjunction with stem cell therapy to enhance efficacy in the regenerative treatment of Chronic Obstructive Pulmonary Disease (COPD).
The Company's Chairman & CEO David Koos stated, "We are excited with this first step in moving towards a specialized laser device that will augment stem cell therapy for treating COPD. We believe the ENT-576 can be utilized to 'paint' damaged lung tissue with laser irradiation allowing stem cells therapeutic treatment to 'spot focus' on the damaged tissue resulting in not only a reduction of progression but also an actual reversal of the effects of COPD."
A spokesperson for Bio-Matrix Scientific Group Inc. (OTCBB: BMSN) noted that it is anticipated this research will start up shortly at its 15,000 sq. ft. stem cell research facility. The projected outcomes of this study will be the development of ENT-576, a specialized laser device, as well as an effective stem cell therapy for treating COPD.
COPD is the 4th leading cause of death in the United States and there is currently no known cure.
About Entest BioMedical Inc.:
Entest BioMedical Inc. (OTCBB: ENTB) is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), immuno-cancer therapies, testing procedures for diabetes, stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation). ENT-576 is a proprietary laser device currently under development by Entest. The Company has filed 3 patent applications relating to the treatment of COPD.
About Bio-Matrix Scientific Group:
Bio-Matrix Scientific Group Inc. (OTCBB: BMSN) is the majority owner of Entest BioMedical Inc. BMSN is a biotechnology company headquartered in San Diego, Ca. with a 15,000 sq. ft. facility that houses two secure cryogenic stem cell banks, three research laboratories, aseptic cellular/tissue class 10,000/100 processing lab, hematology, microbiology and flow cytometry laboratories. David Koos serves as Chairman & CEO concurrently for BMSN and ENTB.
Forward-looking statements:
This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.